Exelixis
EXEL
#1822
Rank
โ‚ฌ9.73 B
Marketcap
38,32ย โ‚ฌ
Share price
-2.41%
Change (1 day)
16.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2025 (TTM): โ‚ฌ2.01 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is โ‚ฌ1.97 Billion. a decrease over the revenue in the year 2024 that were of โ‚ฌ2.08 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2025

Annual revenue

Year Revenue Change
2025 โ‚ฌ1.97 B-5.23%
2024 โ‚ฌ2.08 B25.88%
2023 โ‚ฌ1.65 B10.23%
2022 โ‚ฌ1.50 B18.53%
2021 โ‚ฌ1.26 B57.82%
2020 โ‚ฌ0.80 B-7.06%
2019 โ‚ฌ0.86 B15.75%
2018 โ‚ฌ0.74 B97.91%
2017 โ‚ฌ0.37 B107.18%
2016 โ‚ฌ0.18 B435.39%
2015 โ‚ฌ33.99 M64.66%
2014 โ‚ฌ20.64 M-9.01%
2013 โ‚ฌ22.69 M-36.74%
2012 โ‚ฌ35.87 M-83.92%
2011 โ‚ฌ0.22 B60.31%
2010 โ‚ฌ0.13 B31.34%
2009 โ‚ฌ0.10 B25.64%
2008 โ‚ฌ84.3 M8.48%
2007 โ‚ฌ77.71 M3.92%
2006 โ‚ฌ74.77 M16.62%
2005 โ‚ฌ64.12 M64.56%
2004 โ‚ฌ38.96 M-4.82%
2003 โ‚ฌ40.93 M-3.45%
2002 โ‚ฌ42.39 M-8.68%
2001 โ‚ฌ46.43 M76.67%
2000 โ‚ฌ26.28 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
โ‚ฌ80.32 B 3,959.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚ฌ53.36 B 2,597.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ31.34 B 1,484.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚ฌ45.98 B 2,224.09%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚ฌ55.44 B 2,702.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ41.10 B 1,977.26%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚ฌ37.32 B 1,786.65%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
โ‚ฌ9.93 M-99.50%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
โ‚ฌ80.43 M-95.93%๐Ÿ‡บ๐Ÿ‡ธ USA